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ABSTRACT 74 
Background: Chr17q12-21.2 region is the strongest and most consistently associated region with 75 
asthma susceptibility. The functional genes or single nucleotide polymorphisms (SNPs) are not 76 
obvious due to linkage disequilibrium.  77 
 78 
Objectives: Whole-genome sequence and RNAseq from human bronchial epithelial cells (BEC) 79 
were comprehensively investigated to dissect functional genes/SNPs for asthma severity in the 80 
Severe Asthma Research Program (SARP). 81 
 82 
Methods: eQTL analysis (n=114), correlation analysis (n=156) of gene expression and asthma 83 
phenotypes, and pathway analysis were performed in BEC and replicated. Genetic association 84 
for asthma severity (426 severe vs. 531 non-severe asthma) and longitudinal asthma 85 
exacerbations (n=273) was performed. 86 
 87 
Results: Multiple SNPs in GSDMB associated with asthma severity (odds ratio>1.25) and 88 
longitudinal asthma exacerbations (p<0.05). eQTL analyses identified multiple SNPs associated 89 
with expression levels of PGAP3, GSDMB, or GSDMA (3.1x10-9<p<1.8x10-4). Higher 90 
expression levels of GSDMB correlated with asthma and greater number of exacerbations 91 
(p<0.05). Expression levels of GSDMB correlated with genes involved in interferon signaling, 92 
MHC class I antigen presentation, and immune system pathways (FDR-p<0.05). rs1031458 and 93 
rs3902920 in GSDMB colocalized with interferon regulatory factor (IRF) binding sites and 94 
associated with GSDMB expression, asthma severity, and asthma exacerbations (p<0.05). 95 
 96 
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Conclusions: By using a unique set of gene expression data from lung cells obtained using 97 
bronchoscopy from comprehensively characterized asthma subjects, we show that SNPs in 98 
GSDMB associated with asthma severity, exacerbations, and GSDMB expression levels. 99 
Furthermore, its expression levels correlated with asthma exacerbations and antiviral pathways. 100 
Thus, GSDMB is a functional gene for both asthma susceptibility and severity.101 
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Key Messages 102 
● SNPs in GSDMB were associated with asthma, asthma severity, asthma exacerbations, and 103 
GSDMB expression levels, and its expression levels were correlated with asthma, asthma 104 
exacerbations, and antiviral pathways. 105 
● SNPs in PGAP3-ERBB2, ZPBP2-GSDMB-ORMDL3, and GSDMA regions were associated 106 
with the expression levels of PGAP3, GSDMB, and GSDMA, respectively; SNPs in IKZF3 were 107 
associated with the expression levels of PGAP3, GSDMB, or GSDMA. 108 
● SNPs identified by GWAS of asthma or autoimmune diseases (AD) were also eQTL SNPs for 109 
PGAP3, GSDMB, or GSDMA, but showed opposite effect alleles between asthma and AD. 110 
 111 
Capsule summary 112 
By using a unique dataset of gene expression from lung cells of asthmatics, we show strong 113 
evidence for GSDMB as a gene for asthma severity and asthma exacerbations probably through 114 
antiviral pathways. 115 
 116 
Key words 117 
Antiviral pathways; asthma exacerbations; asthma severity; eQTL; genetics; GSDMA; GSDMB; 118 
PGAP3; whole-genome sequence; RNAseq 119 
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AD: autoimmune diseases 123 
BEC: bronchial epithelial cells 124 
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CD: Crohn’s disease 125 
eQTL: expression quantitative trait loci 126 
ER: emergency room 127 
FDR: false discovery rate 128 
GSDMA: gasdermin A 129 
GSDMB: gasdermin B 130 
GTEx: Genotype-Tissue Expression database 131 
GWAS: genome-wide association study 132 
HRV: human rhinovirus 133 
IBD: inflammatory bowel disease 134 
LD: linkage disequilibrium 135 
MAF: minor allele frequency 136 
MS: multiple sclerosis 137 
ORMDL3: ORMDL sphingolipid biosynthesis regulator 3 138 
PGAP3: post-GPI attachment to proteins 3 139 
PBCh: primary biliary cholangitis 140 
PBCi: primary biliary cirrhosis 141 
QC: quality control 142 
RA: rheumatoid arthritis 143 
RNAseq: RNA sequence 144 
SARP: Severe Asthma Research Program 145 
SLE: systemic lupus erythematosus 146 
SNP: Single nucleotide polymorphism 147 
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SS: systemic sclerosis 148 
TOPMed: Trans-Omics for Precision Medicine 149 
T1D: type I diabetes 150 
UC: ulcerative colitis 151 
WGS: whole-genome sequence 152 
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INTRODUCTION 153 
Asthma is a common inflammatory airway disease. ORMDL3 in chr17q12-21.2 region was the 154 
first gene identified through genome-wide association study (GWAS) of asthma.1 Since then, 155 
GWAS, candidate gene replication, and gene expression studies have consistently identified or 156 
confirmed SNPs in multiple genes in this region that are associated with asthma susceptibility, 157 
including PGAP3,2-4 ERBB2,5 IKZF3,6-9 ZPBP2,10-11 GSDMB,1,5,8,12-20 ORMDL3,11,21-25 and 158 
GSDMA.9,14-15,26 SNPs in IKZF3,27 ZPBP2,28 GSDMB,10,29-30 and PSMD329 have also been 159 
associated with allergic responses. However, partially due to linkage disequilibrium (LD), it has 160 
been difficult to determine the specific genes or SNPs responsible for those association. In 161 
addition, most published GWAS of asthma has tested the association of SNPs with asthma 162 
susceptibility (mild or severe asthma vs. healthy controls), not asthma severity. To analyze 163 
asthma severity, we performed a genetic association analysis for severe asthma compared to non-164 
severe asthma and asthma exacerbations longitudinally over a 3 year period. 165 
 166 
Autoimmune diseases (AD) arise from abnormal immune responses to self-antigens. SNPs in 167 
ERBB2,31 IKZF3,32-44 ZPBP2,45-46 GSDMB,47-58 and GSDMA59-60 have been associated with a 168 
variety of AD. In a previously published GWAS, we were the first to report that the opposite risk 169 
alleles in IL13, TNIP1, HLA-DRA, and GSDMB associated with asthma and AD.61 In this study, 170 
we comprehensively compared all the GWAS-identified SNPs associated with asthma, allergy, 171 
and AD in chr17q12-21 region to reveal genetic effects on the immunopathogenesis of asthma, 172 
allergy, and AD. 173 
 174 
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In a recent review, genetic association, expression quantitative trait loci (eQTL), and epigenetics 175 
of 17 SNPs in chr17q12-21.2 region with asthma have been summarized.62 Proximal (PGAP3-176 
ERBB2), core (IKZF3-ZPBP2-GSDMB-ORMDL3), and distal (GSDMA) regions have been 177 
suggested as independent regions associated with asthma.62 178 
  179 
In order to delineate the functional genes/SNPs for asthma severity in this region, we utilized a 180 
unique dataset of lung gene expression data obtained from bronchial brushing during 181 
investigational bronchoscopy in extensively characterized patients with current asthma plus 182 
healthy controls. We hypothesize that combing SNP with RNA gene expression data from lung 183 
cells of asthmatics, we will be able to determine the functional asthma genes/SNPs in this 184 
complicated chromosomal region. 185 
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METHODS 186 
Study subjects 187 
SARP is a currently active multicenter program funded for the last 18 years by the NHLBI. Mild 188 
to severe subjects with asthma (enriched for severe) and a subset of controls have been 189 
extensively studied using standardized protocols. The earlier SARP cohort was cross-sectional 190 
(n=1,644). In a subset of subjects with mild to severe asthma, RNA was isolated from epithelial 191 
cells (BEC; n=155) that were obtained from brush biopsies (Table I and Table E1).63-65 The 192 
current SARP cohort is an ongoing longitudinal study (n=714).66-68 Bronchoscopy was 193 
performed on a subset of the longitudinal cohort to obtain epithelial cells from brush biopsies 194 
(n=156) for RNAseq (Table I and Table E1). All studies were approved by the appropriate 195 
institutional review board at the participating sites including informed consent. 196 
 197 
Statistical analysis 198 
Selection of SNPs and RNAseq Data. Whole genome sequencing (WGS) in SARP (n=1,888; 199 
version Freeze 6; dbGaP accession: phs001446) was performed through NHLBI-sponsored 200 
TOPMed Program (www.nhlbiwgs.org). Standard quality control (QC) was performed. All SNPs 201 
in chr17q12-21.2 region were extracted (hg38: PPP1R1B to CSF3; chr17:39,626,924-40,017,813) 202 
in the longitudinal cohort with WGS using PLINK 1.9 software,69 and further QC were 203 
performed as described.61,70 Similarly, SNPs were extracted from the cross-sectional cohort with 204 
GWAS data and imputed based on TOPMed reference panel using the Michigan Imputation 205 
Server.71 206 
 207 
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RNAseq data from BEC in the longitudinal cohort were extracted for 14 candidate genes (except 208 
for ZPBP2 and LRRC3C which failed QC) in chr17q12-21.2 region. In brief, Illumina HiSeq 209 
RNAseq reads were quality filtered and mapped to human genome hg38 using STAR package.72 210 
Read counts were regularized logarithm transformed using DESeq2 package.73 The RNAseq data 211 
will be deposited and accessible through GEO (www.ncbi.nlm.nih.gov/geo/). Agilent Whole 212 
Human Genome Microarray expression data of these 16 genes were extracted from BEC in the 213 
cross-sectional cohort as described.74-75 The microarray expression data have been deposited and 214 
can be accessed through GSE63142 and GSE43696.74,76-77  215 
216 
Genetic Association Analysis. Logistic or linear regression, assuming a genetic additive model, 217 
was used for genetic association analysis of asthma severity (426 severe asthma vs. 531 non-218 
severe asthma) and the number of exacerbations (n=273) due to asthma in three years in non-219 
Hispanic White adults (age≥12 years old) in the longitudinal cohort (Table I), adjusted for age, 220 
sex, and the first five components from the multidimensional scaling analysis of genome.  221 
222 
We first investigated a set of 48 candidate SNPs identified by previous GWAS of asthma, allergy, 223 
and AD (NHGRI-EBI GWAS catalog;78 www.ebi.ac.uk/gwas/) incorporated in UCSC genome 224 
browser (genome.ucsc.edu; accessed on August 12, 2019)79 for association with asthma severity 225 
and longitudinal exacerbations in SARP (Figure 1). To reduce multiple tests due to SNPs with 226 
strong LD, the numbers of independent tests were calculated using GEC.80 14.4 independent tests 227 
of 48 candidate SNPs were indicated by GEC, and thus SNPs with p-value<0.0035 (0.05/14.4 228 
tests) were considered significant. SNPs with p-value<0.05 were considered as nominally 229 
significant. From all sequenced SNPs in the chr17q12-21.2 region, we extracted 1,266 common 230 
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SNPs (MAF≥0.01) to test for association and p-value<0.05 was considered as nominally 231 
significant due to relatively small sample size. Note that all of the 48 candidate SNPs were 232 
included in the set of 1,266 common SNPs. LD was estimated with 95% confidence intervals of 233 
D’ to define LD blocks and LD plots of candidate SNPs in chr17q12-21.2 region were generated 234 
separately for 1,016 non-Hispanic Whites and 622 African Americans (Table I) using 235 
Haploview.81 236 
 237 
eQTL Analysis. A linear additive genetic model was used to test the association between SNPs 238 
and inverse normalized expression data as described before.74-75 The longitudinal and cross-239 
sectional cohorts were used as discovery and replication datasets, respectively (Figure 1). 240 
Significant eQTL SNPs identified in the lung tissue (n=383) from Genotype-Tissue Expression 241 
(GTEx) database26 were also evidence for replication (Figure 1). In the longitudinal cohort with 242 
WGS and RNAseq in BEC (n=114), 252.6 independent tests of 862 common SNPs (MAF≥0.05) 243 
in chr17q12-21.2 region were indicated by GEC,80 and thus, SNPs with p-value<1.98x10-4 244 
(0.05/252.6 tests) were considered as significant eQTL SNPs. SNPs with p-value<0.05 were 245 
considered as nominally significant. Conditional eQTL analysis of PGAP3, GSDMB, and 246 
GSDMA in the longitudinal cohort was performed to identify independent eQTL SNPs by 247 
stepwise adjusting the most significant eQTL SNP. 248 
 249 
Colocalization Analysis. To test whether the same SNP (n=862) is responsible for the genetic 250 
association of asthma severity and eQTL of PGAP3, GSDMB, or GSDMA in the longitudinal 251 
cohort (Figure 1), a Bayesian-based colocalization analysis was performed using coloc 252 
package.82 A posterior probability of 75% or greater was considered as strong evidence of 253 
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colocalization. Colocalization analysis of SNPs associated with asthma severity or longitudinal 254 
asthma exacerbations and with gene expression of PGAP3, GSDMB, or GSDMA in the 255 
longitudinal cohort (Figure 1) was also performed through conditional eQTL analysis by 256 
adjusting the most significant SNP associated with ast ma severity or longitudinal asthma 257 
exacerbations. 258 
 259 
Correlation Analysis of Gene Expression and Asthma Phenotypes. Correlation analysis of gene 260 
expression and asthma-related phenotypes was perform d as described (Figure 1).74-75 In brief, a 261 
generalized linear model was used to test the correlation between expression levels of 16 262 
candidate genes and asthma-related phenotypes with adjustment of age, sex, race (dummy 263 
variables for non-Hispanic Whites and African Americans), BMI, and batch effect. P-value<0.05 264 
was considered as nominally significant. 265 
 266 
Pathway Analysis. Correlation analysis of gene exprssion levels of 16,068 genes in the 267 
longitudinal cohort or 19,567 genes in the cross-sectional cohort was performed using 268 
Spearman’s rank correlation. The genes with expression levels significantly correlated with 269 
PGAP3, GSDMB, or GSDMA (p<0.05/16,067=3.1x10-6 in the longitudinal cohort and 270 
p<0.05/19,566=2.5x10-6 in the cross-sectional cohort) were input into Reactome software for 271 
pathway analysis83 (Figure 1). Enriched biological pathways were identified using a 272 
hypergeometric distribution test with false discovery rate (FDR) adjusted p-value<0.05.  273 
 274 
IRF Binding Site Analysis. Interferon regulatory factor (IRF) binding sites were checked for 275 
GSDMB based on ENCODE database (Figure 1).84 Genetic association and eQTL analyses were 276 
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performed for two common SNPs and four rare SNPs (MAF<0.01) in the identified IRF binding 277 
sites of GSDMB. 278 
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RESULTS 279 
Genetic Association Analysis 280 
16 candidate genes in chr17q12-21.2 region (Figure E1) were selected based on the published 281 
GWAS of asthma, allergy, or AD.78 To elucidate shared genetic variants for immune dis ases, 48 282 
SNPs in this region identified through GWAS of asthma, allergy, and AD78-79 or associated with 283 
asthma as reported by Stein t al.62 were investigated (Table II).  284 
 285 
Most of the SNPs previously associated with asthma susceptibility were associated with asthma 286 
severity at the nominal p-value of 0.05 (Table II). rs2305479 and rs62067034 in GSDMB were 287 
significantly associated with asthma severity after multiple-test adjustment (odds ratio=1.34; 288 
p=0.0029<0.0035). When testing 1,266 common SNPs, several independent signals were 289 
associated with asthma severity though no SNP reached a more stringent significance 290 
(p<0.05/1266) (Table E2), including five SNPs in GSDMB (odds ratio>1.3; p<0.0035) with the 291 
risk alleles associated with increased GSDMB expression. 292 
 293 
Most of the SNPs previously associated with asthma susceptibility were also associated with 294 
longitudinal asthma exacerbations at the nominal p-value of 0.05 (Table II). rs2517955 in 295 
PGAP3 was significantly associated with longitudinal asthma exacerbations after multiple-test 296 
adjustment (p=0.0034). When testing 1,266 common SNPs, several independent signals were 297 
associated with longitudinal asthma exacerbations though no SNP reached stringent significance 298 
(p<0.05/1266) (Table E3), including four SNPs in PGAP3-ERBB2 region (p<0.0035) with the 299 
risk alleles associated with increased PGAP3 expression. 300 
 301 
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Multiple SNPs in this region were associated with asthma, allergy, and AD, however, the risk 302 
alleles were opposite between asthma and AD (Table II). For example, the G allele of rs907092 303 
in IKZF3 was the risk allele for asthma (p<5x10-8)7-8 and asthma severity (p=0.027), and 304 
associated with higher expression levels of GSDMB (p=3.7x10-4) and PGAP3 (p=7.9x10-4), but 305 
was the protective allele for primary biliary cholangitis (PBCh) (p<5x10-8).38 The G allele of 306 
rs2305480 (a missense mutation in GSDMB) was the risk allele for asthma (p<5x10-8),14-15 307 
asthma severity (p=0.015), longitudinal asthma exacrbations (p=0.0086) and associated with 308 
higher expression levels of GSDMB (p=2.5x10-5), but was the protective allele for rheumatoid 309 
arthritis (RA) and ulcerative colitis (UC) (p<5x10-8).48,57 The A allele of rs3894194 (a missense 310 
mutation in GSDMA) was the risk allele for asthma (p<5x10-8)14-15 and associated with lower 311 
expression levels of GSDMA (p=4.3x10-4), but was the protective allele for systemic sclerosis 312 
(SS) (p<5x10-8).59 All 48 candidate SNPs identified by previous GWAS (Table II) were common 313 
SNPs (MAF≥0.01), and thus, belonged to 1,266 common SNPs analyzed in this study. When 314 
ranking genetic association of asthma severity p-values of 1,266 SNPs, 35 (73%), 6 (13%), 3 315 
(6%), and 4 (8%) of 48 candidate SNPs were distributed in the 1st to 4th quartile, respectively. 316 
 317 
eQTL Analysis and Colocalization Analysis 318 
Expression of 14 genes (except ZPBP2 and LRRC3C) in the longitudinal cohort (n=114 BEC) 319 
and 16 gene in the cross-sectional cohort (n=120 BEC) passed QC (Table I and Table E1). LD 320 
pruning (r2≥0.8) of 862 common SNPs (MAF≥0.05) belonging to these 16 candidate genes 321 
generated 273 SNPs. The complete eQTL results of 862 SNPs were summarized in Table E4. 322 
 323 
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26 of 273 SNPs were significantly associated with the gene expression levels of PGAP3, 324 
GSDMB, or GSDMA, but not associated with the other genes in the longitudinal cohort (Table III 325 
and Table E4-E5). The eQTL findings of 26 SNPs in the longitudinal cohort were generally 326 
replicated in BEC in the cross-sectional cohort at nominal p-value of 0.05 (Table E6). 327 
Considering stringent replication (p<0.05/26=1.9x10-3), 16 of 26 SNPs in PGAP3 or GSDMB 328 
were replicated in BEC in the cross-sectional cohort; 21 of 26 SNPs in PGAP3, GSDMB, or 329 
GSDMA were replicated in GTEx lung tissue (Table III); all together, 22 of 26 SNPs were 330 
replicated. Three and six LD blocks were formed for these 26 SNPs in non-Hispanic Whites and 331 
African Americans, respectively (Table III, Figure E2-E3). SNPs in PPP1R1B, PGAP3, and 332 
ERBB2 were associated with PGAP3 expression. SNPs in IKZF3 region were associated with the 333 
expression levels of PGAP3, GSDMB, or GSDMA. SNPs in ZPBP2, GSDMB, and ORMDL3 334 
were associated with GSDMB expression. SNPs in GSDMA were associated with GSDMA 335 
expression. Most of these 26 eQTL SNPs were associated with asthma severity or longitudinal 336 
asthma exacerbations at a nominal p-value of 0.05 (Table E7). 337 
 338 
Five and six LD blocks were identified for 48 GWAS-identified SNPs in non-Hispanic Whites 339 
and African Americans, respectively (Table II, Figure E4-E5). Significant eQTL SNPs 340 
(p<0.0035) were associated with the expression levels of three genes (PGAP3, GSDMB, or 341 
GSDMA) in the longitudinal cohort and were generally replicated in the cross-sectional cohort at 342 
nominal p-value of 0.05 (Table II and Table E8). GTEx lung tissue eQTL in this region 343 
identified four genes (PGAP3, GSDMB, ORMDL3, and GSDMA) (Table II and III). 344 
 345 
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Conditional eQTL analysis was performed by stepwise adjusting the most significant eQTL SNP 346 
(Table E9), and indicated that two SNPs (rs2517954 in PGAP3 and rs114211283 in IKZF3), two 347 
SNPs (rs11657449 in ZPBP2-GSDMB and rs3794712 in PPP1R1B), and one SNP (rs3859193 in 348 
GSDMA) were independent eQTL SNPs for PGAP3, GSDMB, and GSDMA, respectively.  349 
 350 
Colocalization analysis82 of the signals from genetic association of asthma severity and eQTL 351 
was performed, and indicated no significant colocalization SNP based on the criterion of 352 
posterior probability>75% (Table E10). rs2517954 in PGAP3, rs11657449 in ZPBP2-GSDMB, 353 
and rs2941522 in GRB7-IKZF3 were top colocalization SNPs for PGAP3, GSDMB, and GSDMA, 354 
respectively (Table E11). Colocalization analysis between SNPs associated with asthma severity 355 
or longitudinal asthma exacerbations and gene expression of PGAP3, GSDMB, and GSDMA was 356 
also performed through conditional eQTL analysis by adjusting the most significant SNP 357 
associated with asthma severity or longitudinal asthma exacerbations (Table E12, Table II). With 358 
adjustment of rs2952156 in ERBB2, rs2305479 in GSDMB, and rs3902025 in GSDMA, all eQTL 359 
SNPs for PGAP3 (except for rs114211283 in IKZF3), for GSDMB (except for two SNPs in 360 
PPP1R1B and ZPBP2-GSDMB), and for GSDMA became non-significant. For example, the 361 
association between GSDMB expression and rs11657449 in ZPBP2-GSDMB or rs3794712 in 362 
PPP1R1B was weakened when adjusting for rs2305479, indicating that rs2305479 partly 363 
accounted for the eQTL association but not completely. In summary, the colocalization analyses 364 
did not show strong evidence for colocalization. 365 
 366 
Expression Analysis and Pathway Analysis 367 
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The risk alleles associated with asthma, asthma severity, and longitudinal asthma exacerbations 368 
were associated with higher expression levels of PGAP3 and GSDMB or the lower expression 369 
levels of GSDMA (Table II), which indicated that expression levels of PGAP3, GSDMB, and 370 
GSDMA may be correlated with asthma phenotypes. 371 
 372 
Correlation analysis of gene expression (PGAP3, GSDMB, and GSDMA) and asthma phenotypes 373 
was performed in BEC in the longitudinal cohort (n=156) and replicated in BEC (n=155) in the 374 
cross-sectional cohort (Table IV). Higher expression levels of GSDMB were correlated with 375 
asthma (p=0.05), greater number of exacerbations in the last 12 months (p=0.02), and higher 376 
reduction of ACQ-6 after steroid treatment (p=0.0008) in the longitudinal cohort. Higher 377 
expression levels of GSDMB were correlated with emergency room (ER) visits or 378 
hospitalizations due to asthma in the last 12 months (p=0.03) in the cross-sectional cohort. Other 379 
asthma-related phenotypes were not correlated with expression levels of PGAP3, GSDMB, or 380 
GSDMA (Table E13), except that higher expression levels of GSDMB were correlated with 381 
higher FeNO (p=0.03) in the longitudinal cohort. Although correlation analysis was focused on 382 
PGAP3, GSDMB, and GSDMA, the other 13 genes were also analyzed (Table E14-E15). Higher 383 
expression of PNMT and lower expression of CSF3 were associated with asthma susceptibility in 384 
BEC in the longitudinal and cross-sectional cohorts. 385 
 386 
Pathway analyses were performed on the genes with expression levels significantly correlated 387 
with PGAP3, GSDMB, or GSDMA. No biological pathways were identified for the genes 388 
correlated with PGAP3 or GSDMA after FDR adjustment (data not shown). 435 and 677 genes 389 
were positively and negatively correlated with GSDMB (p<3.1x10-6) in BEC in the longitudinal 390 
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cohort, among which 636 genes were replicated in BEC in the cross-sectional cohort (p<0.05) 391 
(Table E16). Pathway analysis83 was performed on 1,112 and 462 genes with expression levels 392 
significantly correlated with GSDMB expression in BEC in the longitudinal cohort (p<3.1x10-6) 393 
and cross-sectional cohort (p<2.5x10-6), respectively. Expression levels of GSDMB were 394 
correlated with genes involved in interferon alpha/beta/gamma signaling, MHC class I antigen 395 
presentation, and immune system pathways (FDR-p<0.05) (Table V and Table E17). 396 
 397 
IRF Binding Site Analysis 398 
Interferon regulatory factor (IRF) binding sites were checked for GSDMB and two regions were 399 
identified based on ENCODE database (Figure E6).84 One IRF1/2 biding site was located at 400 
5’UTR-exon 1-intron 1 region of GSDMB (Figure E7) and one IRF4 biding site was located at 401 
intron 2 of GSDMB (Figure E8). Two common SNPs and four rare SNPs were found in these 402 
two IRF biding sites based on SARP WGS (Table VI). Two common SNPs (rs1031458 and 403 
rs3902920) were associated with GSDMB expression, asthma severity, and longitudinal asthma 404 
exacerbations (p<0.05), making them potential functio al SNPs. 405 
 406 
T allele of rs1031458 or C allele of rs3902920 were risk alleles for asthma severity and 407 
longitudinal asthma exacerbations (Table VI), and they were also associated with early onset of 408 
asthma (p<0.005) (Table E18) especially atopic early onset (age onset of asthma<6 yrs) asthma 409 
(p<0.00001) (Table E19 and Figure 2). Similarly, most f the top 10 SNPs associated with 410 
asthma severity (including rs3902920; Table E2) were also associated with asthma severity in 411 
the subjects with early onset asthma (onset<6 yrs) (Table E20). rs1031458 and rs3902920 were 412 
in strong LD (r2≥0.8) with multiple neighboring SNPs (Table II-III) in non-Hispanic Whites 413 
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(Table E21). In African Americans, rs1031458 and rs3902920 were in strong LD with three 414 
(rs921650, rs7216389, and rs201413617) and zero neighboring SNPs, respectively. 415 
 416 
In summary, by using a unique set of gene expression data from lung cells of asthmatics obtained 417 
using investigative bronchoscopy and by performing comprehensive genetic association, 418 
expression correlation, eQTL, and pathway analyses, w  have narrowed down chr17q12-21.2 419 
region (16 candidate genes; 390 kbp) to two SNPs in GSDMB associated with asthma severity 420 
and asthma exacerbations potentially through antiviral pathways (Figure 1).  421 
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DISCUSSION 422 
Almost all the SNPs identified by previous GWAS in GSDMB now show to be associated with 423 
asthma severity and longitudinal asthma exacerbations, indicating that SNPs in GSDMB are 424 
associated with asthma susceptibility, asthma severity, and asthma exacerbations. Asthma and 425 
AD share extensive immunological pathways, however, the risk alleles of the same associated 426 
SNPs in this region are consistently opposite for asthma and AD, which may indicate distinct 427 
immunopathogenesis processes. In addition to SNPs with MAF≥0.01, we also investigated rare 428 
SNPs (MAF<0.01; n=4,006) for association with asthma severity. 14 rare SNPs were associated 429 
with asthma severity at nominal p-value of 0.05 with large effect size (2.9<odds ratio<12) (Table 430 
E22). Replication of these rare SNPs is needed in larger cohorts with sequence data and asthma 431 
phenotypes. In conclusion, findings from genetic association of asthma susceptibility, asthma 432 
severity, and asthma exacerbations in this region are generally consistent, however, genetic 433 
association analysis can not narrow down the 16 candidate genes due to strong and complicated 434 
LD structure in this region. 435 
436 
Gene expression is dependent on cell type or tissue, time, and environmental factors such as 437 
disease status. It is critical that cells are obtained from the appropriate organ (lung for asthma) 438 
and from living subjects with the disease being investigated instead of from surgical specimens 439 
(usually from cancer patients) or autopsy specimens. Even findings of eQTL analyses in lung 440 
cells are not always consistent (Table E23). The most significant eQTL genes were GSDMA 441 
followed by GSDMB and ORMDL3 in two eQTL studies in lung tissue.26,85 Nicodemus-Johnson 442 
et al. identified ORMDL3 but not GSDMB in an eQTL analysis in BEC.4 Our eQTL analysis in 443 
BEC in both longitudinal and cross-sectional cohorts74 identified GSDMB but not ORMDL3. 444 
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Similarly, a recent genetic association and eQTL study has shown that eQTL SNPs for GSDMB 445 
(but not ORMDL3) in BEC play a major role in childhood asthma in African Americans.86 BEC 446 
obtained from brush biopsies are mainly composed of epithelial cells, although small proportion 447 
of basal cells and immune cells also exist. A flow cytometry study showed that 95% to 97% of 448 
the cells from bronchial brushings were epithelial cel s.87 In this study, cell populations were not 449 
available for every subject, and thus, were not adjusted. Future eQTL and expression analyses by 450 
adjusting cell composition or single-cell RNAseq may reveal interesting results. 451 
 452 
SNPs in PGAP3-ERBB2 region were associated with PGAP3 expression and longitudinal asthma 453 
exacerbations. In a previous GWAS, rs2941504 in PGAP3 has been associated with asthma.2 454 
Another GWAS has identified rs2952156 in ERBB2 associated with asthma5 nd PGAP3 455 
expression in lung tissue.26 Thus, SNPs in PGAP3-ERBB2 are associated with asthma 456 
phenotypes by up-regulating PGAP3 gene expression. The first GWAS of asthma has identified 457 
rs7216389 in GSDMB associated with childhood asthma and the expression levels of ORMDL3 458 
and GSDMB in lymphoblastoid cell lines.1 In this study, rs7216389 was significantly associated 459 
with GSDMB expression (p=1.7x10-4) but not ORMDL3 (p=0.22) in BEC. Thus, SNPs in 460 
ZPBP2-GSDMB-ORMDL3 are associated with asthma phenotypes by up-regulating GSDMB 461 
gene expression. rs3894194 in GSDMA has been associated with asthma14-15 and the expression 462 
levels of GSDMA in lung tissue.26 In this study, rs3894194 was significantly associated with 463 
GSDMA expression (p=4.3x10-4). Thus, SNPs in GSDMA are associated with asthma phenotypes 464 
by down-regulating GSDMA gene expression. Interestingly, SNPs in IKZF3 were not 465 
consistently associated with a specific gene expression, instead, associated with the expression 466 
levels of PGAP3, GSDMB, or GSDMA, which may indicate long-distance gene expression 467 
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regulation. Interaction between gene regulatory elem nts and genes shown by GeneHancer88 also 468 
indicated IKZF3 was involved in complicated long-distance regulation of GSDMB, GSDMA, 469 
ORMDL3, and ERBB2 (Figure E9). In summary, our findings confirm the hypothesis that there 470 
are proximal, core, and distal regions independently associated with asthma.62 In addition, IKZF3 471 
forms a long-distance regulation region. More importantly, we narrowed down 16 candidate 472 
genes to three genes (PGAP3, GSDMB, and GSDMA). 473 
 474 
We attempted to identify functional SNPs using coloa ization and conditional eQTL analyses. 475 
rs2517954 for PGAP3 and rs11657449 for GSDMB were identified by both colocalization 476 
analysis and conditional eQTL analysis, though the posterior probability of colocalization was 477 
not high. The probable reason is that the signals of genetic association are not strong due to 478 
sample size, and thus, eQTL signals drive the colocalization findings in SARP. Colocalization 479 
analysis through conditional eQTL analysis (Table E12) further indicates that the colocalization 480 
analysis based on the Bayesian approach does not show strong evidence for colocalization. 481 
 482 
Previous studies have shown inconsistent relationshp between gene expression in this region and 483 
asthma susceptibility.62 The mRNA levels of ORMDL3 in lymphoblastoid cell lines have not 484 
been significantly different in children with or without asthma.1 An immunohistochemistry study 485 
has found that GSDMB protein levels are significantly higher in subjects with asthma than 486 
controls.89 In this study, higher mRNA levels of GSDMB were correlated with asthma and 487 
asthma exacerbations, though the correlation was not trong and not always consistently 488 
significant. Although our findings are based on relevant tissues (BEC) in relevant subjects 489 
(healthy controls, non-severe and severe asthma), subjects involved in this study are all adults 490 
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(age≥12 years old). Typical of adult asthma cohorts, the SARP cohort consists of those with 491 
early onset of asthma and those with older age onset.63,67 Since asthma is often an early-onset 492 
disease, expression or eQTL analyses in children would be interesting but, of course, research 493 
bronchoscopies are not performed in children. In this study, gene expression correlation and 494 
eQTL analyses were performed in all SARP subjects with mixed races to increase sample size 495 
and power. Although gene expression is less influenced by population stratification than genetic 496 
association, the findings may still be biased due to different allele frequencies and LD structures 497 
in different ethnic groups. Correlation analysis of gene expression (PGAP3, GSDMB, and 498 
GSDMA) and asthma phenotypes (Table IV) and eQTL analysis of top five eQTL SNPs for these 499 
three genes (Table E4) were also performed in SARP non-Hispanic Whites (Table E24 and Table 500 
E25). The findings of gene expression correlation and eQTL analyses were similar between non-501 
Hispanic Whites and all subjects with mixed races. In summary, the association of SNPs in 502 
GSDMB, the expression levels of GSDMB, and asthma phenotypes make GSDMB a strong 503 
candidate for severe asthma. 504 
 505 
The function of PGAP3, GSDMB, or GSDMA is not totally understood. PGAP3 may have a role 506 
in controlling autoimmunity and Th1/Th2 balance.90 GSDMA may regulate or be regulated by 507 
TGF-β1 and mediate immune defense by inducing pyroptosis.91 GSDMB may regulate apoptosis 508 
of epithelial cells and upregulate expression of airw y remodeling genes, chemokines, and heat-509 
shock proteins.89,91 In this study, the expression levels of GSDMB are positively correlated with 510 
MHC class I molecules (HLA-A/-B/-C/-F), type I interferon (STAT1, STAT2, and IRF9) and type 511 
II interferon pathway genes (IFN-γ and STAT1), and Th1 pathway genes (IFN-γ, STAT1, IL18R1, 512 
and IL18BP). All these biological pathways are related to antiviral process, indicating that virus 513 
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infection and expression of antiviral pathway genes may lead to severe asthma and asthma 514 
exacerbations. rs7216389 in GSDMB has been associated with human rhinovirus (HRV) induced 515 
wheezing illnesses in children and increased expression of GSDMB and ORMDL3 in HRV-516 
stimulated peripheral-blood mononuclear cells, which further indicates the potential interaction 517 
of GSDMB and virus infection in asthma pathogenesis.92 In a previous gene expression analysis 518 
in human nasal epithelial cells, GSDMB expression can be induced by IFN-α stimulation.93 In 519 
this study, two SNPs (rs1031458 and rs3902920) in the promoter region of GSDMB are 520 
colocalized with IRF binding sites and associated with GSDMB expression, atopic early onset 521 
asthma, asthma severity, and longitudinal asthma exacerbations, making them potential 522 
functional SNPs. 523 
524 
One main disadvantage of this study is the relatively small sample size. In genetic association, 525 
eQTL, and gene expression correlation analyses, nominal p-values of 0.05 in addition to adjusted 526 
p-values have been used. Furthermore, the replication results in several datasets are not always527 
consistently significant. Thus, it requires careful interpretation as for significance and replication. 528 
One main advantage of this study is that multi-level evidence point to the same gene (GSDMB). 529 
530 
In conclusion, we identified that three independent signals (PGAP3, GSDMB, and GSDMA) were 531 
associated with asthma susceptibility and GSDMB was also associated with asthma severity, 532 
asthma exacerbations, and antiviral pathways. Future candidate gene studies in large, multi-533 
ethnic, or children with asthma and functional experiments may further reveal functional 534 
SNPs/genes for asthma including rare variants in this important region.535 
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Figure Legends 536 
537 
FIG 1.  Flow chart of genetic analyses in chr17q12-21.2 region 538 
539 
FIG 2. Risk allele frequency of rs1031458 (A) and rs3902920 (B) in GSDMB stratified by age 540 
onset of asthma and atopic status. Chi-square test was performed by comparing each asthma 541 
group with general North-Western European controls shown in red line (gnomAD V2.1.1; 542 
https://gnomad.broadinstitute.org/). 543 
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TABLE I. Demographics (mean±SDs) of subjects in SARP 819 
  
RNAseq (BEC)  
Longitudinal 
Microarray (BEC)  
Cross-sectional 
WGS† 











n 156 114 155 120 426 531 273 1,016 622 
Age 41±13 41±13 37±13 36±13 46±15 37±15 47±16 39±17 29±17 
Female, n (%) 99 (63) 74 (65) 101 (65) 80 (67) 269 (63) 353 (66) 176 (64) 656 (65) 369 (59) 
BMI 30±8.1 30±8.7 30±6.8 30±7.0 31±7.7 28±7.6 31±7.9 29±7.9 30±11 
Race (Non-Hispanic White/African American/Other*), % 67/24/9 65/26/9 62/29/9 60/29/11 100/0/0 100/0/0 100/0/0 100/0/0 0/100/0 
Baseline % predicted FEV1 82±21 76±20 76±22 76±23 66±22 84±17 73±21 77±21 78±20 
Baseline FEV1/FVC 0.73±0.10 0.70±0.10 0.72±0.12 0.71±0.13 0.66±0.13 0.75±0.09 0.69±0 11 0.72±0.12 0.72±0.11 
Asthma status (Control/Non-severe/Severe), n 42/49/65 0/49/65 27/78/50 19/60/41 0/0/426 0/531/0 0/111/162 0/564/451 0/270/252 
Age Onset of Asthma<18 yrs, n (%) 77 (68) 77 (68) 88 (71) 69 (68) 238 (56) 348 (66) 164 (60) 645 (64) 394 (75) 
Note: BEC: bronchial epithelial cell brushing; Microarray: Agilent Whole Human Genome Microarray 4x44K v2; WGS: whole-820 
genome sequence; GWAS: genome-wide association study. 821 
*Other races include Hispanic, Asian, American Indian, and mixed. 822 
†1,016 non-Hispanic Whites and 622 African Americans in SARP longitudinal and cross-sectional cohorts with WGS were used for 823 
LD calculation; Among 1,016 non-Hispanic Whites, 957 adults (age≥12 yrs) (426 with severe asthma vs. 531 with non-severe 824 
asthma) were included in the genetic association analysis of asthma severity; 273 adults in the longitudinal cohort were included in the 825 
genetic association analysis of longitudinal asthma exacerbations. 826 
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TABLE II. Genetic association and eQTL results of 48 GWAS-identified SNPs associated with expression levels of PGAP3, GSDMB, 827 










Number of  
Exacerbations 
in 3 years††† 
eQTL of SARP3 in BEC (n=114) 
eQTL of GTEx database  
Lung Tissue (n=383) 
Effect 
Allele 






β (P)  
rs2941504* 39674647 synonymous PGAP3 A/G 
Asthma2; 
eQTL for PGAP33 
1 1 







A ~ PGAP3↑ (2E-10); 
ORMDL3↑ (1E-7); GSDMA↓ (4E-6) 







C ~ PGAP3↑ (1E-12); 
ORMDL3↑ (2E-6) 
rs2952156*† 39720582 intronic ERBB2 A/G Asthma5 
2 
  







A ~ PGAP3↑ (4E-10); ORMDL3↑ (4E-9); 
GSDMA↓ (7E-6); GSDMB↑ (2E-5) 








rs2941522† 39754115 intergenic 
GRB7 
-IKZF3 







T ~ GSDMB↑ (3E-15); ORMDL3↑ (4E-15); 
GSDMA↓ (1E-6); PGAP3↑ (1E-6) 





MS3 ; IBD32-33 35 
2 







T ~ GSDMB↓ (2E-9); ORMDL3↓ (9E-9);  
GSDMA↑ (1E-6) 







A ~ GSDMB↓ (3E-5) 











G ~ GSDMB↑ (2E-9);  
ORMDL3↑ (5E-9); GSDMA↓ (2E-7) 







C ~ GSDMB↑ (7E-10);  
ORMDL3↑ (3E-9); GSDMA↓ (3E-8) 







T ~ ORMDL3↑ (1E-5);  
GSDMB↑ (2E-5); PGAP3↑ (2E-5) 
rs9303277*† 39820216 intronic IKZF3 T/C 
PBCh39- 2; SS3; 
SLE 3 







T ~ GSDMB↓ (7E-15); ORMDL3↓ (6E-14); 
GSDMA↑ (2E-7); PGAP3↓ (7E-6) 















C ~ GSDMB↓ (1E-5); 
ORMDL3↓ (2E-5); PGAP3↓ (2E-5) 













A ~ ORMDL3↑ (4E-9); 
GSDMA↓ (2E-8); GSDMB↑ (7E-8) 
rs11655198† 39869916 intronic ZPBP2  (C/T) Asthma10 
3 







C ~ GSDMB↑ (6E-15); ORMDL3↑ (8E-12); 
GSDMA↓ (8E-7); PGAP3↑ (3E-6) 
rs12936231* 39872867 intronic ZPBP2 (C/G)  
ORMDL3 promoter11 







C ~ GSDMB↑ (5E-15); ORMDL3↑ (1E-14); 
GSDMA↓ (1E-7); PGAP3↑ (8E-6) 






















C ~ ORMDL3↓ (7E-10); GSDMB↓ (3E-9);  
GSDMA↑ (4E-9); 
rs12232497† 39883866 intergenic 
ZPBP2 
-GSDMB 







C ~ ORMDL3↓ (7E-10); GSDMA↑ (3E-9);  
GSDMB↓ (3E-9) 




RA 8- 9; T1D50; 
UC51; CD52-53 







A ~ ORMDL3↓ (3E-10); GSDMB↓ (5E-10); 
GSDMA↑ (2E-9) 
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rs12936409† 39887396 intergenic 
ZPBP2 
-GSDMB 







T ~ ORMDL3↓ (8E-10); GSDMA↑ (4E-9);  
GSDMB↓ (9E-9) 
rs8067378† 39895095 intergenic ZPBP2 
-GSDMB 






G ~ GSDMB↓ (5E-15); ORMDL3↓ (1E-14); 
GSDMA↑ (1E-7); PGAP3↓ (8E-6) 
rs12453507† 39896954 intergenic 
ZPBP2 
-GSDMB 







G ~ GSDMB↓ (2E-15); ORMDL3↓ (2E-12); 
GSDMA↑ (2E-8); PGAP3↓ (1E-6) 
rs8069176*† 39900944 intergenic 
ZPBP2 
-GSDMB 







G ~ ORMDL3↑ (6E-11); GSDMA↓ (1E-10);  
GSDMB↑ (2E-10) 







T ~ ORMDL3↑ (1E-10); GSDMA↓ (2E-10);  
GSDMB↑ (7E-10) 




RA 8; UC57 







G ~ ORMDL3↑ (1E-10); GSDMA↓ (2E-10); 
 GSDMB↑ (2E-9) 







C ~ GSDMB↑ (6E-15); ORMDL3↑ (4E-15); 
GSDMA↓ (1E-7); PGAP3↑ (5E-6) 







C ~ GSDMB↑ (2E-15); ORMDL3↑ (1E-12);  
GSDMA↓ (1E-7); PGAP3↑ (7E-6) 







C ~ ORMDL3↑ (1E-10); 











T ~ ORMDL3↑ (8E-11); GSDMA↓ (4E-10); 
 GSDMB↑ (8E-10) 






















T ~ GSDMB↑ (8E-16); ORMDL3↑ (7E-15); 
GSDMA↓ (1E-8); PGAP3↑ (3E-6) 







C ~ ORMDL3↑ (2E-10); GSDMB↑ (3E-10); 
GSDMA↓ (5E-10) 






C ~ GSDMB↑ (1E-15); ORMDL3↑ (2E-12);  
GSDMA↓ (2E-7); PGAP3↑ (3E-6) 







A ~ GSDMB↑ (1E-15); ORMDL3↑ (8E-13); 
GSDMA↓ (2E-7); PGAP3↑ (3E-6) 







T ~ GSDMB↑ (1E-15); ORMDL3↑ (8E-13); 
GSDMA↓ (2E-7); PGAP3↑ (3E-6) 
rs9303280† 39917778 intronic GSDMB C/T Allergy30 
  







C ~ GSDMB↑ (3E-15); ORMDL3↑ (2E-12); 
GSDMA↓ (3E-9); PGAP3↑ (9E-6) 







G ~ GSDMB↑ (1E-13); ORMDL3↑ (1E-13); 
GSDMA↓ (6E-11) 







A ~ GSDMA↓ (1E-11); ORMDL3↑ (7E-11); 
 GSDMB↑ (1E-9) 
rs12603332* 39926554 5' UTR ORMDL3 C/T 
eQTL and meQTL for  
ORMDL3/GSDMB22-23 
4 5 







C ~ ORMDL3↑ (2E-14); GSDMB↑ (2E-13); 
GSDMA↓ (6E-12); PGAP3↑ (2E-5) 







G ~ GSDMA↓ (2E-17); ORMDL3↑ (2E-11);  
GSDMB↑ (2E-8) 












C ~ GSDMA↓ (6E-21); GSDMB↑ (9E-8);  
ORMDL3↑ (2E-5) 
rs3902025† 39963001 5' UTR GSDMA C/A SS59 
6 







C ~ GSDMA↑ (2E-21); ORMDL3↓ (9E-7);  
GSDMB↓ (1E-5) 












A ~ GSDMA↓ (1E-21); GSDMB↑ (4E-9);  
ORMDL3↑ (2E-7) 
rs7212938† 39966427 missense GSDMA G/T Asthma9 
    







G ~ GSDMA↓ (3E-18); GSDMB↑ (1E-7);  
ORMDL3↑ (5E-5) 







T ~ GSDMA↓ (5E-52) 
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Note: entries with p-value<0.0035 for genetic association analysis of asthma severity or longitudinal asthma exacerbations were labeled in red color. NS: non-829 
significant; NA: non-available. 830 
*17 SNPs associated with asthma and reported by Stein et al.62 831 
†SNPs associated with asthma, allergy, and autoimmune diseases from NHGRI-EBI GWAS catalog (www.ebi.ac.uk/gwas/),78 incorporated in UCSC genome 832 
browser (genome.ucsc.edu; accessed on March 1, 2019).79 833 
‡Risk allele/Other allele: parenthesis indicates risk allele was not reported in the original study but predicted based on available data. 834 
**AD: autoimmune diseases; CD: Crohn’s disease; IBD: inflammatory bowel disease; MS: multiple sclerosis; PBCh: primary biliary cholangitis; PBCi: primary 835 
biliary cirrhosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SS: systemic sclerosis; T1D: type I diabetes; UC: ulcerative colitis. 836 
†† LD was estimated with 95% confidence intervals of D’ to define LD blocks of 48 SNPs for 1,016 non-Hispanic Whites (NHW) and 622 African Americans 837 
(AA) in SARP longitudinal cohort and cross-sectional cohort with WGS using Haploview.81 838 
***OR and P were odds ratio and p-value for genetic association analysis of asthma severity (426 severe s. 531 non-severe asthma) in non-Hispanic White in 839 
SARP. 840 
†††β and P were correlation coefficient and p-value for genetic association analysis of the number of longitudinal exacerbations due to asthma in 3 years in the 841 
longitudinal cohort in 273 asthmatics with longitudinal asthma exacerbations in non-Hispanic White in SARP.842 
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TABLE III. eQTL results of 26 SNPs significantly associated with expression levels of PGAP3, GSDMB, or GSDMA in the 843 









SARP3 BEC (n=114) 
eQTL of GTEx database 
Lung Tissue (n=383)† A1 
PGAP3 GSDMB GSDMA 
β P β P β P 
rs3751903 39627534 PPP1R1B 
1 
1 
C 0.43 0.002 0.55 1.0E-4 -0.10 0.5 C ~ PGAP3↑ (1E-7) 
rs3794712 39635234 PPP1R1B A 0.48 0.007 0.78 6.5E-6 0.06 0.7 NS 
rs10558975 39675051 PGAP3   G -0.54 1.1E-5 -0.32 0.01 0 13 0.3 
G ~ PGAP3↓ (1E-13); ORMDL3↓ (2E-5);  
GSDMB↓ (6E-5) 
rs907088 39677314 PGAP3 
2 
G 0.69 3.3E-7 0.32 0.02 -0.27 0.06 G ~ PGAP3↑ (1E-12); ORMDL3↑ (8E-8) 
rs2517954 39687297 PGAP3 T 0.77 3.1E-9 0.25 0.08 -0.29 0.04 T ~ PGAP3↑ (9E-10); ORMDL3↑ (3E-8) 
rs2904765 39692422 PGAP3-ERBB2 
  
T 0.70 8.7E-6 0.17 0.3 -0.34 0.04 NS 
rs56328874 39694273 PGAP3-ERBB2   A -0.72 1.0E-4 0.16 0.4 0 26 0.2 NS 
rs2517951 39696844 PGAP3-ERBB2 
2 
3 
T -0.58 1.6E-6 -0.29 0.02 0 13 0.3 
T ~ PGAP3↓ (1E-13); ORMDL3↓ (2E-6);  
GSDMB↓ (2E-5) 
rs2952155 39705465 ERBB2 T 0.72 4.6E-7 0.31 0.04 -0.23 0.1 T ~ PGAP3↑ (2E-8); ORMDL3↑ (1E-6) 
rs2934967 39714125 ERBB2 G 0.79 9.9E-9 0.25 0.08 -0.29 0.05 
G ~ PGAP3↑ (5E-11); ORMDL3↑ (2E-8);  
GSDMB↑ (4E-5); GSDMA↓ (6E-6) 
rs2941520 39747477 GRB-IKZF3 
4 
T 0.70 1.7E-6 0.30 0.05 0.01 0.9 
T ~ PGAP3↑ (2E-10); ORMDL3↑ (3E-9);  
GSDMB↑ (1E-6) 
rs2941519 39747478 GRB-IKZF3 G -0.36 0.01 -0.15 0.3 0 52 1.6E-4 
G ~ ORMDL3↓ (5E-14); GSDMB↓ (6E-13);  
PGAP3↓ (5E-6); GSDMA↑ (3E-5) 
rs9747973 39748854 GRB-IKZF3 C -0.41 0.003 -0.34 0.01 0 53 1.0E-4 
C ~ GSDMB↓ (2E-15); ORMDL3↓ (7E-15);  
GSDMA↑ (6E-7); PGAP3↓ (1E-6) 
rs12450323 39816455 IKZF3 
  
T 0.63 1.5E-4 0.43 0.01 0 13 0.4 
T ~ ORMDL3↑ (1E-5); GSDMB↑ (2E-5);  
PGAP3↑ (2E-5) 
rs114211283 39819840 IKZF3 A 1.11 3.5E-5 0.13 0.6 0 12 0.7 NS 
rs62066988 39836028 IKZF3   T -0.35 0.02 -0.56 1.4E-4 0 31 0.04 
T ~ ORMDL3↓ (2E-6); GSDMB↓ (2E-5);  
GSDMA↑ (4E-5) 
rs9635726 39863888 IKZF3 
3 
T 0.63 1.3E-4 0.47 0.005 0.07 0.7 
T ~ GSDMB↑ (1E-5); ORMDL3↑ (2E-5);  
PGAP3↑ (2E-5) 
rs4795397 39867492 IKZF3-ZPBP2 
5 
G -0.40 0.003 -0.52 1.0E-4 0.42 0.002 
G ~ ORMDL3↓ (4E-9); GSDMA↑ (2E-8);  
GSDMB↓ (7E-8) 
rs12150079 39869164 ZPBP2 A -0.38 0.01 -0.59 5.7E-5 0 32 0.03 
A ~ ORMDL3↓ (3E-7); GSDMB↓ (6E-6);  
GSDMA↑ (7E-6) 
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rs11651596 39899863 ZPBP2-GSDMB 
6 
C -0.36 0.008 -0.62 1.6E-6 0 32 0.02 
C ~ ORMDL3↓ (2E-10); GSDMA↑ (3E-10);  
GSDMB↓ (2E-9) 
rs11657449 39901588 ZPBP2-GSDMB C -0.34 0.02 -0.69 7.5E-7 0 32 0.03 
C ~ ORMDL3↓ (2E-7); GSDMA↑ (7E-7);  
GSDMB↓ (6E-6) 
rs1011082 39912261 GSDMB 
  
T -0.33 0.01 -0.51 6.6E-5 0 31 0.02 
T ~ GSDMB↓ (8E-16); ORMDL3↓ (6E-13);  
GSDMA↑ (1E-7); PGAP3↓ (4E-7) 
rs201413617 39917590 GSDMB-ORMDL3 G -0.33 0.01 -0.48 1.6E-4 0 27 0.04 NS 
rs4795405 39932164 ORMDL3-LRRC3C T -0.35 0.01 -0.51 1.6E-4 0.45 0.0009 
T ~ GSDMA↑ (3E-14); ORMDL3↓ (1E-10);  
GSDMB↓ (p=6E-10) 
rs9914973 39966455 GSDMA 
  
C -0.42 0.002 -0.22 0.1 0 52 1.7E-4 C ~ GSDMA↑ (9E-17) 
rs3859193 39969603 GSDMA A 0.31 0.02 0.13 0.3 -0.50 7.2E-5 A ~ GSDMA↓ (9E-30); GSDMB↑ (5E-7) 
Note: entries with p-value<1.98x10-4 were labeled in red color. β and P were correlation coefficient and p-value of eQTL analysis. 845 
BEC: bronchial epithelial cells brushing. NS: non-significant. 846 
*LD was estimated with 95% confidence intervals of D’ to define LD blocks of 26 SNPs for 1,016 non-Hispanic Whites (NHW) and 847 
622 African Americans (AA) in SARP longitudinal cohort and cross-sectional cohort with WGS using Haploview.81 848 
†eQTL of GTEx database: eQTL SNPs identified in the lung tissue (n=383) from Genotype-Tissue Expression (GTEx) database.26 849 
↑indicated up-regulation of gene expression and ↓i icated down-regulation of gene expression.  850 
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TABLE IV.  Correlation of the expression levels of PGAP3, GSDMB, or GSDMA and asthma phenotypes in SARP 851 
RNAseq (156 BEC) in the longitudinal cohort 
Gene 
Asthma Susceptibility Asthma Severity 
Number of Exacerbations  
(last 12 months) 
∆ACQ6  
























PGAP3 8.81±0.22 8.88±0.20 0.08 8.90±0.21 8.87±0.20 0.33 -0.84 0.57 -0.12 0.77 
GSDMB 9.94±0.25 10.1±0.32 0.05 10.1±0.28 10.1±0.35 0.89 2.11 0.019 -0.81 0.0008 
GSDMA 0.50±0.15 0.55±0.22 0.26 0.52±0.19 0.57±0.24 0.29 -1.40 0.27 0.14 0.69 
Microarray (155 BEC) in the cross-sectional cohort 
Gene 
Asthma Susceptibility Asthma Severity 
ER or Hospitalization  



















PGAP3 10.8±0.22 10.8±0.33 0.43 10.8±0.34 10.8±0.31 0.63 10.8±0.35 10.8±0.29 0.57 
GSDMB 10.5±0.42 10.4±0.47 0.15 10.4±0.45 10.4±0.51 0.23 10.3±0.46 10.5±0.49 0.03 
GSDMA 6.26±0.15 6.21±0.13 0.02 6.21±0.14 6.21±0.12 0.56 6.21±0.13 6.20±0.13 0.41 
Note: a general linear model was used to test the correlation between gene expression levels (natural logarithm transformed in the longitudinal cohort or log2 852 
transformed in the cross-sectional cohort) and asthma phenotypes with adjustment of age, sex, race, BMI, and batch effect.853 
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Table V. Biological pathways enriched for genes with expression levels correlated with GSDMB expression in BEC in the 854 
longitudinal cohort 855 
Pathway Gene 
P value  
(FDR) 
Interferon gamma signaling 
CIITA, HLA-A, HLA-B, HLA-C, HLA-F, IFNG, IFNGR2, IL20RA, IRF9,  
MID1, OAS2, OAS3, PML, SP110, SP140L, STAT1, SUMO1, TRIM14,  
TRIM22, TRIM25, TRIM26, TRIM38 2.3E-14 
Interferon alpha/beta signaling 
BST2, HLA-A, HLA-B, HLA-C, HLA-F, IFI27, IRF9, MX2, OAS2, OAS3, 
STAT1, STAT2, USP18, XAF1 2.3E-14 
Antigen Presentation  
(Folding, assembly and peptide loading of class I MHC) HLA-A, HLA-B, HLA-C, HLA-F, SEC24B, TAP1, TAP2, TAPBP 2.3E-14 
ER-Phagosome pathway 
HLA-A, HLA-B, HLA-C, HLA-F, IKBKB, PSMB9, PSMD8, PSME2, RAPSN, 
TAP1, TAP2, TAPBP 2.3E-14 
Interferon Signaling 
BST2, CIITA, HLA-F, IFI27, IFNG, IFNGR2, IL20RA, IRF9, MAPK1, MID1, 
MX2, NUP210, OAS2, OAS3, PML, SP110, SP140L, STAT1, STAT2, SUMO1, 
TRIM14, TRIM22, TRIM25, TRIM26, TRIM38, UBA7, USP18, XAF1 2.3E-14 
Endosomal/Vacuolar pathway HLA-A, HLA-B, HLA-C, HLA-F 2.3E-14 
Antigen processing-Cross presentation 
HLA-A, HLA-B, HLA-C, HLA-F, IKBKB, ITGB5, PSMB9, PSMD8, PSME2, 
RAPSN, TAP1, TAP2, TAPBP 2.3E-14 
Class I MHC mediated antigen processing & presentation 
ASB14, ASB4, ASB8, FBXL3, FBXO2, FBXO21, FBXO41, HLA-A, HLA-B, 
HLA-C, HLA-F, IKBKB, ITGB5, NARF, PJA2, POLL, PSMB9, PSMD8,  
PSME2, RAPSN, RBX1, RNF213, SEC24B, SIAH1, SKP1, TAP1, TAP2,  
TAPBP, TRIM36, TRIM39, UBA7, UBE2D2, UBE2D4, UBE2E3 3.5E-13 
Immunoregulatory interactions  
(between a Lymphoid and a non-Lymphoid cell) CD226, CLEC2D, HLA-A, HLA-B, HLA-C, HLA-F, RAET1E 6.3E-11 
Cytokine Signaling in Immune system 
ATF1, ATF2, CALM2, CIITA, CRKL, DUSP16, FASLG, HLA-A, HLA-B,  
HLA-C, HLA-F, IFI27, IKBKB, IL18BP, IL20RA, IL37, IL6ST, IRF9,  
LAMTOR3, LGALS9, LIFR, MID1, MX2, NDN, PDGFA, PML, PSME2,  
PTPN14, PTPN4, RBX1, SKP1, SP110, STAT1, STAT2, STAT6, TRIM14, 
TRIM22, TRIM25, TRIM26, TRIM38 7.9E-08 
Adaptive Immune System 
ACTR10, ASB4, ASB8, ASB14, BLNK, BTF3, BTN2A1, BTN2A2, BTN3A1, 
CALM2, CARD11, CD74, CLEC2D, DCTN3, DCTN6, FBXL3, FBXO41, 
GRAP2, HLA-A, HLA-B, HLA-C, IKBKB, MAP3K14, POLL, PSMD8,  
RAET1E, SEC24B, SIAH1, SKP1, TAP1, TAP2, TBCB, TEP1, TRIM36,  
TRIM39, UBA7, UBE2D2, UBE2D4, UBE2E3, ZAP70 9.7E-03 
Note: pathways with false discovery rate (FDR)-adjusted p-value less than 0.05 were included.856 
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Number of  
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in 3 years‡ 
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(n=383)†† 





















ORMDL3↓ (3E-19)  
GSDMA↑ (1E-14) 
PGAP3↓ (1E-7) 






























































NA NA NA NA 
*Minor allele (effect allele)/major allele (minor allele frequency). 858 
†OR and P were odds ratio and p-value for genetic association analysis of asthma severity (426 severe vs. 531 non-severe asthma) in non-Hispanic White in 859 
SARP. 860 
‡β and P were correlation coefficient and p-value for genetic association analysis of the number of longitudinal exacerbations due to asthma in 3 years in the 861 
longitudinal cohort in 273 asthmatics with longitudinal asthma exacerbations in non-Hispanic White in SARP. 862 
** β and P were correlation coefficient and p-value for eQTL analysis in 114 subjects with RNAseq of bronchial epithelial cells in SARP longitudinal cohort. 863 
††eQTL of GTEx database: eQTL SNPs identified in the lung tissue (n=383) from Genotype-Tissue Expression (GTEx) database.26 ↑indicat d up-regulation of 864 
gene expression and ↓indicated down-regulation of gene expression. NA: non-avaliable and NS: non-significant. 865 











